Avanos Medical Earnings Call Transcripts
Fiscal Year 2026
-
Streamlined operations and divested underperforming assets while focusing on specialty nutrition and pain management. Achieved strong 2025 results, set mid-single-digit growth targets, and outlined a path to $1 billion revenue by 2030 through organic growth and targeted acquisitions. Product innovation and tariff mitigation remain key priorities.
-
Management outlined a focused strategy for long-term growth, emphasizing operational efficiency, global expansion, and targeted M&A. Specialty nutrition and pain management segments are driving revenue, with new products and tariff mitigation supporting future growth.
Fiscal Year 2025
-
Delivered strong 2025 results, exceeding revised sales and earnings guidance, with robust growth in Specialty Nutrition Systems and Pain Management & Recovery. 2026 guidance anticipates continued organic growth, margin improvement in the second half, and successful tariff mitigation as China exit completes.
-
Q3 delivered double-digit organic growth in strategic segments, raised full-year guidance, and completed key portfolio moves including the Nexus Medical acquisition and HA divestiture. Cost savings and tariff mitigation efforts are underway, with strong liquidity supporting future M&A.
-
Second quarter saw strong organic growth in core segments, robust demand, and the divestiture of the HA product line. Full-year revenue and EPS guidance were reaffirmed despite tariff and macroeconomic headwinds, with continued focus on transformation and cost management.
-
Leadership changes and organizational restructuring are driving efficiency and growth, with a strong focus on innovation, premiumization, and global supply chain improvements. Despite tariff headwinds and slower category growth, margins have rebounded, and investments in brands and new products remain robust.
-
Q1 2025 saw strong organic growth in Specialty Nutrition Systems and solid progress in Pain Management and Recovery, with robust cash flow and a maintained revenue outlook. Tariffs and executive transition costs led to a lower adjusted EPS range, but transformation initiatives and M&A activity continue to support growth.
Fiscal Year 2024
-
Q4 and full-year results showed strong organic growth in Enteral Feeding and solid progress in transformation initiatives, despite a significant impairment charge and ongoing HA pricing pressures. 2025 guidance anticipates stable sales and earnings, with continued focus on portfolio optimization and M&A in Specialty Nutrition Systems.
-
Leadership changes and transformation efforts continued, with Q3 sales at $170M and adjusted EPS of $0.36. Digestive health outperformed, while pain management lagged due to supply issues. Q4 guidance calls for $175–$180M revenue and improved margins.
-
Q2 2024 saw strong organic growth in Digestive Health and momentum in Pain Management, with adjusted EBITDA up 17% and EPS up 42% year-over-year. Guidance for 2024 is reaffirmed, and transformation priorities are on track to meet 2025 targets.